80 related articles for article (PubMed ID: 22586000)
1. Antiangiogenic drugs increase xenograft aggressiveness.
Cancer Discov; 2012 Mar; 2(3):OF3. PubMed ID: 22586000
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Reimer CL; Agata N; Tammam JG; Bamberg M; Dickerson WM; Kamphaus GD; Rook SL; Milhollen M; Fram R; Kalluri R; Kufe D; Kharbanda S
Cancer Res; 2002 Feb; 62(3):789-95. PubMed ID: 11830534
[TBL] [Abstract][Full Text] [Related]
3. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Pan Q; Kleer CG; van Golen KL; Irani J; Bottema KM; Bias C; De Carvalho M; Mesri EA; Robins DM; Dick RD; Brewer GJ; Merajver SD
Cancer Res; 2002 Sep; 62(17):4854-9. PubMed ID: 12208730
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
[TBL] [Abstract][Full Text] [Related]
6. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
7. Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents.
Konson A; Pradeep S; Seger R
Cancer Res; 2010 Aug; 70(15):6247-57. PubMed ID: 20610633
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
9. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment.
Dong D; Ko B; Baumeister P; Swenson S; Costa F; Markland F; Stiles C; Patterson JB; Bates SE; Lee AS
Cancer Res; 2005 Jul; 65(13):5785-91. PubMed ID: 15994954
[TBL] [Abstract][Full Text] [Related]
10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
11. A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Lyons JM; Anthony CT; Thomson JL; Woltering EA
Ann Surg Oncol; 2008 Dec; 15(12):3407-14. PubMed ID: 18795370
[TBL] [Abstract][Full Text] [Related]
12. Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo.
Park HJ; Kim SR; Kim MK; Choi KS; Jang HO; Yun I; Bae SK; Bae MK
Cancer Lett; 2011 Dec; 312(1):117-27. PubMed ID: 21908103
[TBL] [Abstract][Full Text] [Related]
13. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.
Rofstad EK; Henriksen K; Galappathi K; Mathiesen B
Cancer Res; 2003 Jul; 63(14):4055-61. PubMed ID: 12874006
[TBL] [Abstract][Full Text] [Related]
15. Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.
Hutchinson LG; Mueller HJ; Gaffney EA; Maini PK; Wagg J; Phipps A; Boetsch C; Byrne HM; Ribba B
CPT Pharmacometrics Syst Pharmacol; 2016 Nov; 5(11):636-645. PubMed ID: 27863175
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer.
Ademuyiwa FO; Miller KD
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S151-6. PubMed ID: 19158035
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
18. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
19. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]